Greasley, Peter J.

The orphan receptor GPR55 is a novel cannabinoid receptor

Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology

Cannabis and Cannabinoid ResearchReceptor Mechanisms and Signaling

Cited by 1,568

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 531

Why do SGLT2 inhibitors reduce heart failure hospitalization? Adifferential volume regulation hypothesis

Hallow, K. M., Helmlinger, G., Greasley, P. J., McMurray, J. J. V., & Boulton, D. W. (2018) · Diabetes, Obesity and Metabolism

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 499

Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial

Cherney, D. Z. I., Dekkers, C. C. J., Barbour, S. J., Cattran, D., Abdul Gafor, A. H., Greasley, P. J., Laverman, G. D., Lim, S. K., Di Tanna, G. L., Reich, H. N., et al. (2020) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 283

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

Jackson, A. M., Dewan, P., Anand, I. S., Bělohlávek, J., Bengtsson, O., de Boer, R. A., Böhm, M., Boulton, D. W., Chopra, V. K., DeMets, D. L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 175

Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of the DAPASALT Trial

Scholtes, R. A., Muskiet, M. H. A., van Baar, M. J. B., Hesp, A. C., Greasley, P. J., Karlsson, C., Hammarstedt, A., Arya, N., van Raalte, D. H., & Heerspink, H. J. L. (2021) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 125

Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes

Dekkers, C. C. J., Sjöström, C. D., Greasley, P. J., Cain, V., Boulton, D. W., & Heerspink, H. J. L. (2019) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 106

Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data

Hallow, K. M., Greasley, P. J., Helmlinger, G., Chu, L., Heerspink, H. J., & Boulton, D. W. (2018) · American Journal of Physiology-Renal Physiology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 68